Completed PHASE4 INTERVENTIONAL 3-arm NCT01789762

Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP)

Sponsor: Etablissement Français du Sang

Conditions Aplasia With Expected Thrombocytopenia

Interventions Additive solution Autologous plasma Pathogen reduction process

Updated 7 times since 2017 Last updated: Apr 26, 2019 Started: May 31, 2013 Primary completion: Jan 31, 2016 Completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Aplasia With Expected Thrombocytopenia, this trial is completed. The trial is conducted by Etablissement Français du Sang and has accumulated 7 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
May 2019 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — May 2019 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Etablissement Français du Sang
University Hospital, Grenoble

Data source: Etablissement Français du Sang

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Besançon, France , Brest, France , Clermont-Ferrand, France , Créteil, France , Dijon, France , Grenoble, France , Lille, France , Marseille, France , Paris, France , Pierre-Bénite, France and 2 more locations